These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 19075055

  • 1. Virologic failure in first-line human immunodeficiency virus therapy with a CCR5 entry inhibitor, aplaviroc, plus a fixed-dose combination of lamivudine-zidovudine: nucleoside reverse transcriptase inhibitor resistance regardless of envelope tropism.
    Demarest JF, Amrine-Madsen H, Irlbeck DM, Kitrinos KM, CCR102881 Clinical Study Team.
    Antimicrob Agents Chemother; 2009 Mar; 53(3):1116-23. PubMed ID: 19075055
    [Abstract] [Full Text] [Related]

  • 2. Virologic failure in therapy-naive subjects on aplaviroc plus lopinavir-ritonavir: detection of aplaviroc resistance requires clonal analysis of envelope.
    Kitrinos KM, Amrine-Madsen H, Irlbeck DM, Word JM, Demarest JF, CCR100136 Study Team.
    Antimicrob Agents Chemother; 2009 Mar; 53(3):1124-31. PubMed ID: 19075068
    [Abstract] [Full Text] [Related]

  • 3. Antiviral activity and safety of aplaviroc with lamivudine/zidovudine in HIV-infected, therapy-naive patients: the ASCENT (CCR102881) study.
    Currier J, Lazzarin A, Sloan L, Clumeck N, Slims J, McCarty D, Steel H, Kleim JP, Bonny T, Millard J, ASCENT study team.
    Antivir Ther; 2008 Mar; 13(2):297-306. PubMed ID: 18505181
    [Abstract] [Full Text] [Related]

  • 4. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.
    Irlbeck DM, Amrine-Madsen H, Kitrinos KM, Labranche CC, Demarest JF.
    AIDS; 2008 Jul 31; 22(12):1425-31. PubMed ID: 18614865
    [Abstract] [Full Text] [Related]

  • 5. Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection.
    Landovitz RJ, Angel JB, Hoffmann C, Horst H, Opravil M, Long J, Greaves W, Fätkenheuer G.
    J Infect Dis; 2008 Oct 15; 198(8):1113-22. PubMed ID: 18783318
    [Abstract] [Full Text] [Related]

  • 6. HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry.
    Tilton JC, Amrine-Madsen H, Miamidian JL, Kitrinos KM, Pfaff J, Demarest JF, Ray N, Jeffrey JL, Labranche CC, Doms RW.
    AIDS Res Hum Retroviruses; 2010 Jan 15; 26(1):13-24. PubMed ID: 20055594
    [Abstract] [Full Text] [Related]

  • 7. Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study.
    Henry K, Wallace RJ, Bellman PC, Norris D, Fisher RL, Ross LL, Liao Q, Shaefer MS, TARGET Study Team.
    J Infect Dis; 2001 Feb 15; 183(4):571-8. PubMed ID: 11170982
    [Abstract] [Full Text] [Related]

  • 8. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.
    Staszewski S, Keiser P, Montaner J, Raffi F, Gathe J, Brotas V, Hicks C, Hammer SM, Cooper D, Johnson M, Tortell S, Cutrell A, Thorborn D, Isaacs R, Hetherington S, Steel H, Spreen W, CNAAB3005 International Study Team.
    JAMA; 2001 Mar 07; 285(9):1155-63. PubMed ID: 11231744
    [Abstract] [Full Text] [Related]

  • 9. Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection.
    Eron JJ, Yetzer ES, Ruane PJ, Becker S, Sawyer GA, Fisher RL, Tolson JM, Shaefer MS.
    AIDS; 2000 Apr 14; 14(6):671-81. PubMed ID: 10807190
    [Abstract] [Full Text] [Related]

  • 10. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team).
    Descamps D, Flandre P, Calvez V, Peytavin G, Meiffredy V, Collin G, Delaugerre C, Robert-Delmas S, Bazin B, Aboulker JP, Pialoux G, Raffi F, Brun-Vézinet F.
    JAMA; 2000 Jan 12; 283(2):205-11. PubMed ID: 10634336
    [Abstract] [Full Text] [Related]

  • 11. Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only?
    Stephan C, Dauer B, Khaykin P, Stuermer M, Gute P, Klauke S, Staszewski S.
    Curr HIV Res; 2009 May 12; 7(3):320-6. PubMed ID: 19442129
    [Abstract] [Full Text] [Related]

  • 12. Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy.
    Averbuch D, Schapiro JM, Lanier ER, Gradstein S, Gottesman G, Kedem E, Einhorn M, Grisaru-Soen G, Ofir M, Engelhard D, Grossman Z.
    Pediatr Infect Dis J; 2006 Nov 12; 25(11):1049-56. PubMed ID: 17072129
    [Abstract] [Full Text] [Related]

  • 13. Detection of HIV-1 CXCR4 tropism and resistance in treatment experienced subjects receiving CCR5 antagonist-Vicriviroc.
    McNicholas P, Vilchez RA, Greaves W, Kumar S, Onyebuchi C, Black T, Strizki JM.
    J Clin Virol; 2012 Oct 12; 55(2):134-9. PubMed ID: 22824230
    [Abstract] [Full Text] [Related]

  • 14. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine or stavudine, each in combination with lamivudine and indinavir.
    Descamps D, Flandre P, Joly V, Meiffrédy V, Peytavin G, Izopet J, Tamalet C, Zeng AF, Harel M, Lastère S, Aboulker JP, Yéni P, Brun-Vézinet F, NOVAVIR (ANRS 073) Study Group.
    J Acquir Immune Defic Syndr; 2002 Dec 15; 31(5):464-71. PubMed ID: 12473833
    [Abstract] [Full Text] [Related]

  • 15. Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team.
    Nachman SA, Stanley K, Yogev R, Pelton S, Wiznia A, Lee S, Mofenson L, Fiscus S, Rathore M, Jimenez E, Borkowsky W, Pitt J, Smith ME, Wells B, McIntosh K.
    JAMA; 2000 Jan 26; 283(4):492-8. PubMed ID: 10659875
    [Abstract] [Full Text] [Related]

  • 16. Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.
    Masquelier B, Neau D, Boucher S, Lavignolle-Aurillac V, Schrive MH, Recordon-Pinson P, Ragnaud JM, Fleury H.
    Antivir Ther; 2006 Jan 26; 11(6):827-30. PubMed ID: 17310827
    [Abstract] [Full Text] [Related]

  • 17. Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (study COL40263).
    Ross L, Elion R, Lanier R, Dejesus E, Cohen C, Redfield RR, Gathe JC, Hsu RK, Yau L, Paulsen D, Ha B, COL40263 Study Team.
    AIDS Res Hum Retroviruses; 2009 Jul 26; 25(7):665-72. PubMed ID: 19563238
    [Abstract] [Full Text] [Related]

  • 18. Clinical impact of the M184V mutation on switching to didanosine or maintaining lamivudine treatment in nucleoside reverse-transcriptase inhibitor-experienced patients.
    Winters MA, Bosch RJ, Albrecht MA, Katzenstein DA, AIDS Clinical Trials Group 364 Study Team.
    J Infect Dis; 2003 Aug 15; 188(4):537-40. PubMed ID: 12898440
    [Abstract] [Full Text] [Related]

  • 19. Abacavir/lamivudine/zidovudine maintenance after standard induction in antiretroviral therapy-naïve patients: FREE randomized trial interim results.
    Sprenger HG, Langebeek N, Mulder PG, Ten Napel CH, Vriesendorp R, Hoepelman AI, Legrand JC, Koopmans PP, Van Kasteren ME, Bravenboer B, Ten Kate RW, Groeneveld PH, van der Werf TS, Gisolf EH, Richter C.
    AIDS Patient Care STDS; 2010 Jun 15; 24(6):361-6. PubMed ID: 20515418
    [Abstract] [Full Text] [Related]

  • 20. Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection.
    Ruane P, Lang J, DeJesus E, Berger DS, Dretler R, Rodriguez A, Ward DJ, Lim ML, Liao Q, Reddy S, Clair MS, Vila T, Shaefer MS.
    HIV Clin Trials; 2006 Jun 15; 7(5):229-36. PubMed ID: 17162316
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.